Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter]
Author Department
Pediatrics
Document Type
Response or Comment
Publication Date
2-2025
Recommended Citation
Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T, Bell KJ, Besser REJ, Bonifacio E, Colhoun HM, Couper JJ, Craig ME, Danne T, de Beaufort C, Dovc K, Dutta S, Ebekozien O, Elding Larsson H, Frohnert BI, Gallagher MP, Greenbaum CJ, Griffin KJ, Hagopian W, Haller MJ, Hendriks E, Holt RIG, Ismail HM, Jacobsen LM, Kolb LE, Kordonouri O, Lange K, Lash RW, Lernmark Å, Libman I, Lundgren M, Maahs DM, Marcovecchio ML, Mathieu C, Oron T, Patil SP, Rewers MJ, Rich SS, Schatz DA, Schulman-Rosenbaum R, Simmons KM, Sims EK, Skyler JS, Speake C, Steck AK, Tonyushkina KN, Veijola R, Wentworth JM, Wherrett DK, Wood JR, Ziegler AG, DiMeglio LA. Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter]. Diabetologia. 2025 Feb 12. doi: 10.1007/s00125-024-06350-x. Epub ahead of print.
PMID
39934371
